Evidence map›Paper›PMID 40371781›Full record

ArticleProtein science : a publication of the Protein Society2025

Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils.

Samuel Bismut, Matthias M Schneider, Masashi Miyasaki, Yuqing Feng, Ellis J Wilde, M Dylan Gunawardena, Tuomas P J Knowles, Gabrielle S Kaminski Schierle, Laura S Itzhaki, Janet R Kumita

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils.Protein science : a publication of the Protein Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samuel BismutDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Matthias M SchneiderYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
Masashi MiyasakiDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Yuqing FengDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Ellis J WildeDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
M Dylan GunawardenaDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Tuomas P J KnowlesYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
Gabrielle S Kaminski SchierleDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Laura S ItzhakiDepartment of Pharmacology, University of Cambridge, Cambridge, UK.ORCID 0000-0001-6504-2576
Janet R KumitaDepartment of Pharmacology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-3887-4964

Funding

Alzheimer's Research UK ARUK-PG013-14European Research Council 101001615Medical Research Council MR/K02292X/1Medical Research Council MR/W01632X/1Michael J. Fox Foundation for Parkinson's Research 022159Michael J. Fox Foundation for Parkinson's Research 16238Rosetrees Trust CF2\100013Royal Society RGS\R1\231207Wellcome TrustWellcome Trust 065807/Z/01/ZWellcome Trust 203249/Z/16/Z
6 · The paper itself

Abstract

Amyloid fibrils are ordered aggregates that are a pathological hallmark of many neurodegenerative disorders including Alzheimer's disease and Parkinson's disease. The process of amyloid formation involves a complex cascade by which soluble monomeric protein converts to insoluble, ordered aggregates (amyloid fibrils). Although inhibiting the aggregation pathway is a key target for therapeutic development, the heterogeneous collection of aggregation-prone species formed in this process, including oligomers, protofibrils, and fibrils, represents other targets for modifying disease pathology. Developing molecules that can bind to amyloid fibrils and potentially disrupt the harmful interactions between the fibrils and the cellular components would be advantageous. Designing peptide modulators for α-synuclein aggregation is of great interest; however, effective inhibitory peptides are often hydrophobic and hence difficult to handle. Therefore, developing strategies to display these peptides in a soluble scaffold would be very beneficial. Here we demonstrate that the ultra-stable consensus-designed tetratricopeptide repeat (CTPR) protein scaffold can be grafted with "KLVFF" derived peptides previously identified to inhibit protein aggregation and interact with amyloid fibrils to produce proteins that bind along the surface of α-synuclein fibrils with micromolar affinity. Given the ability to insert hydrophobic peptides to produce soluble, CTPR-based binders, this method may prove beneficial in screening for peptide modulators of protein aggregation.

Indexed as

alpha-SynucleinAmyloidPeptidesHumansProtein Bindingalpha-SynucleinAmyloidPeptidesamyloid fibrilsfibril‐bindersprotein scaffoldsα‐synuclein

Identifiers

PMID40371781
PMCPMC12079352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.